Gregory Oakes - 28 Feb 2023 Form 4 Insider Report for Landos Biopharma, Inc.

Role
Chief Executive Officer, Director
Signature
/s/ Gregory Oakes
Issuer symbol
N/A
Transactions as of
28 Feb 2023
Net transactions value
$0
Form type
4
Filing time
02 Mar 2023, 15:13:17 UTC
Previous filing
22 Jun 2022
Next filing
04 Mar 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LABP Employee Stock Option (right to buy) Award $0 +475,300 $0.000000 475,300 28 Feb 2023 Common Stock 475,300 $0.3700 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/4th of the shares initially subject to the option shall vest on the one (1) year anniversary of the date of grant (such anniversary being the "Anniversary Date") and 1/48th of the shares initially subject to the option shall vest on each monthly anniversary of the Anniversary Date thereafter, subject to the Reporting Person's continuous service with the Issuer on each such date.